Principaux documents

Voir toute la documentation

SML2104

Ambrisentan

Name: Ambrisentan
Brand: SIGMA

≥98% (HPLC), Endothelin ETA Receptor Antagonist, powder

Synonyme(s) :

(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :

C₂₂H₂₂N₂O₄

Numéro CAS:

177036-94-1

Poids moléculaire :

378.42

NACRES:

NA.77

UNSPSC Code:

41121706

MDL number:

MFCD08672619

Assay:

≥98% (HPLC)

Form:

powder

Service technique

Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.

Laissez-nous vous aider

Propriétés

Nom du produit

Ambrisentan, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +160 to +190°, c = 0.5 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1=CC(C)=NC(O[C@@H](C(C2=CC=CC=C2)(OC)C3=CC=CC=C3)C(O)=O)=N1

InChI

1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)

InChI key

OUJTZYPIHDYQMC-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Ambrisentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It is 200-fold selective for the the ETA receptor subtype with a Ki of 1 nM for ETA and a Ki of 195 nM for ETB.

Endothelin ETA Receptor Antagonist; Antihypertensive; Pulmonary Hypertension Treatment

Still not finding the right product?

Explore all of our products under

pictograms

GHS08

signalword

Danger

hcodes

H360FD

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ambrisentan: a review of its use in pulmonary arterial hypertension.

Belinda N Rivera-Lebron et al.

Therapeutic advances in respiratory disease, 11(6), 233-244 (2017-04-21)

Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH

Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.

Johanna Weiss et al.

European journal of pharmacology, 660(2-3), 298-304 (2011-04-20)

The safety and effectiveness of drugs used to treat chronic diseases critically depend on their propensity to interact with co-administered drugs. Induction of enzymes and drug transporters involved in the clearance and distribution of drugs may critically reduce exposure with

Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.

James A Angus et al.

European journal of pharmacology, 804, 111-116 (2017-03-17)

Endothelin receptor antagonists are approved for pulmonary arterial hypertension. Development of selective ET Human isolated pulmonary (i.d. 5.5mm) and human radial (i.d. 3.23mm) artery ring segments were mounted in organ baths for isometric force measurement. Single concentration-contraction curves to endothelin-1

Afficher tous les articles scientifiques apparentés